These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 9766614

  • 21. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM, Leucht S, Carpenter D, Docherty JP, Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [Abstract] [Full Text] [Related]

  • 22. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
    Nasrallah HA.
    J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients.
    Cutler NR.
    J Clin Psychiatry; 2001; 62 Suppl 5():10-3; discussion 23-4. PubMed ID: 11305842
    [Abstract] [Full Text] [Related]

  • 24. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI.
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Improving drug development: exploratory clinical studies.
    James JS.
    AIDS Treat News; 1999 Jan 08; (No 310):6. PubMed ID: 11366150
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.
    J Ment Health Policy Econ; 2008 Jun 08; 11(2):89-97. PubMed ID: 18509216
    [Abstract] [Full Text] [Related]

  • 30. Evaluating clinical trial data: outcome measures.
    Conley RR.
    J Clin Psychiatry; 2001 Jun 08; 62 Suppl 9():23-6; discussion 27-8. PubMed ID: 11379827
    [Abstract] [Full Text] [Related]

  • 31. Clinical effects of a randomized switch of patients from clozaril to generic clozapine.
    Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K.
    J Clin Psychiatry; 2001 Jun 08; 62 Suppl 5():14-7; discussion 23-4. PubMed ID: 11305843
    [Abstract] [Full Text] [Related]

  • 32. Investigational drug tracking: phases I-III and NDA submissions--Part II.
    Grant KL.
    Hosp Pharm; 1994 Oct 08; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
    Aman MG, Gharabawi GM, Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities.
    J Clin Psychiatry; 2004 Sep 08; 65(9):1197-210. PubMed ID: 15367046
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Accelerated approval of oncology products: a decade of experience.
    Dagher R, Johnson J, Williams G, Keegan P, Pazdur R.
    J Natl Cancer Inst; 2004 Oct 20; 96(20):1500-9. PubMed ID: 15494600
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.